Tag: myocardial infarction

Arthritis Drug May Curb Myocardial Damage in Acute STEMI

Early use of tocilizumab (Actemra) does not reduce myocardial infarct size but modestly increases myocardial salvage in patients with acute ST-segment elevation myocardial infarction (STEMI),...

Long Work Hours Tied to Double the Risk for Recurrent MI

Patients who work upward of 55 hours per week after a myocardial infarction (MI) may increase their risk of having a recurrence, a new study...

Target-Lesion Failure Reduced After MI With Biodegradable Stent

For a primary composite target-lesion failure outcome, a biodegradable polymer sirolimus-eluting stent showed superiority at 2 years over a durable polymer everolimus-eluting stent in patients...

Missed Visits During Pandemic Cause ‘Detrimental Ripple Effects’

More than one third of adults aged 18-64 years in the United States delayed or went without medical care because of efforts by patients or...

New Light Cast on Type-2 MI Aims to Sharpen Diagnosis, Therapy

The hospital and post-discharge course of patients diagnosed with type-2 myocardial infarction (MI), triggered when myocardial oxygen demand outstrips supply, differs in telling ways from...

Radial-to-Backup Artery Switch Adds Limited Risk in ACS PCI

There’s a price to pay for a failed radial artery attempt in invasively managed patients with acute coronary syndrome (ACS), but it may not be...

Carotid Surgery Still Too Risky With Contralateral Occlusion

Patients selected for carotid revascularization who have a contralateral carotid occlusion are still best triaged toward stenting rather than surgery, a new registry analysis suggests....

More Evidence Supports Early Anticoagulation in COVID-19

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Early initiation of prophylactic anticoagulation in COVID-19 patients newly admitted to...

GME Funding Tied to Better Outcomes, Resident Scores

Graduate medical education (GME) funding is linked with better patient outcomes and resident academic performance but did not boost hospitals’ bottom line, according to an...

Tofacitinib for RA Misses the Mark in Safety Study

Daily treatment with tofacitinib (Xeljanz) led to more malignancies and adverse cardiovascular events in older rheumatoid arthritis patients compared with treatment with a tumor necrosis...

Cardio Societies Call for Urgent Action

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Four leading cardiovascular organizations — the World Heart Federation (WHF), American...

Full-Dose Anticoagulation Reduces Need for Life Support in COVID-19

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Full-dose anticoagulation was superior to low, prophylactic doses in reducing the...

Air Pollution Linked to Acute Increase in MI Mortality

In a time-stratified, case-crossover study, exposure to both large and small particulate matter, as well as to nitrogen dioxide, was significantly associated with increased odds...

ACEIs, ARBs Safe to Continue in COVID-19: Trial Published

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. The BRACE-CORONA trial ― the first randomized trial to address the...

Sickle-Cell Trait May Not Independently Elevate CHD Risk

African Americans with sickle-cell trait (SCT), that is, who are heterozygous for the sickle-cell gene variant, don’t as a result necessarily have an elevated risk...

NETs a Possible Therapeutic Target for COVID-19 Thrombosis?

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Researchers in Madrid may have found a clue to the pathogenesis...

Even for Wealthy, US Healthcare Can’t Match Care in Other Nations

(Reuters Health) – When it comes to health care, even privileged white Americans fare worse than the average citizens of 12 other developed countries, a...

Lp(a) and LPA Gene Score ‘Modest’ Predictors of CVD Risk

Although lipoprotein(a) (Lpa) levels and LPA genetic risk scores are both significantly associated with atherosclerotic cardiovascular disease (ASCVD) events, they appear to offer only a...

ICI for Cancer Ups Cardiac Event Risk: Danish Data

Immune checkpoint inhibitors (ICIs) increase the risk of cardiac events, including fatal heart attack and stroke, in patients with cancer, an analysis of Danish national...

Ambulatory BP Monitoring Reliability Questioned for HTN Diagnosis

Although guidelines generally recommend ambulatory over home blood pressure (BP) monitoring for diagnosing hypertension, new research questions home BP monitoring’s role as second fiddle. One...

LDL Not the Primary Culprit in ASCVD?

Two new studies suggest that low-density lipoprotein cholesterol (LDL-C) may be not the main driver of atherosclerotic cardiovascular disease (ASCVD). The findings instead implicate remnant...

Fracking Sites Tied to Increased Heart Failure Hospitalizations

Living near hydraulic fracturing is associated with increased risk of hospitalization in people with heart failure (HF), a new study from Pennsylvania suggests. The link...

Calcium Burden Drives CV Risk Whether CAD Is Obstructive or Not

Coronary artery calcium (CAC) score as a measure of plaque burden more reliably predicts future cardiovascular (CV) risk in patients with suspected coronary disease (CAD)...

Incidence of Stroke, But Not MI, Increasing in Young People

Although the incidence of stroke is increasing steadily among young adults, the incidence of acute myocardial infarction (AMI) remains stable, a new analysis suggests. This...

Many Patients With Type 2 MI Don’t Get Cardiologist Evaluation

Perhaps 40% of hospitalized patients with type 2 myocardial infarction (MI) are not evaluated by a cardiologist at the same admission, suggests a study based on...